Birth Defects Research: New Study Findings
- - scientists have pinpointed a novel vulnerability in cytomegalovirus (CMV), a common herpes virus responsible for birth defects and complications in immunocompromised individuals.
- CMV, characterized by its large genome and intricate molecular mechanisms, has historically eluded effective prophylactic treatments.
- The GATE complex enables CMV to infiltrate cells lining blood vessels, causing internal damage while simultaneously preventing immune recognition.
Scientists have made a groundbreaking finding, identifying a new target for CMV vaccine development. The research reveals the GATE protein complex, which the cytomegalovirus utilizes to invade cells and evade immune responses. This novel finding promises to revolutionize treatments and prevention strategies for an elusive herpes virus linked to birth defects. Previously, CMV has resisted effective vaccines, but the identification of GATE offers a promising avenue for progress. This coudl perhaps lead to better outcomes for infants and immunocompromised patients. Explore how this target offers potential hope for new antiviral drugs. Read more from News Directory 3. Discover whatS next …
new Target Identified for Cytomegalovirus vaccine Development
Updated June 30, 2025
La Jolla, Calif. – scientists have pinpointed a novel vulnerability in cytomegalovirus (CMV), a common herpes virus responsible for birth defects and complications in immunocompromised individuals. The breakthrough identifies a protein complex, called GATE, that CMV uses to enter cells and evade immune detection, paving the way for new CMV vaccine strategies.
CMV, characterized by its large genome and intricate molecular mechanisms, has historically eluded effective prophylactic treatments. Like other herpes viruses, CMV relies on the gH protein to infect cells. However,unlike its relatives,CMV replaces the typical gL protein partner with UL116 and recruits UL141 to form the GATE complex.
The GATE complex enables CMV to infiltrate cells lining blood vessels, causing internal damage while simultaneously preventing immune recognition.
Researchers believe targeting GATE could revolutionize the approach to CMV vaccine development and treatment of other herpes viruses.
“Previous attempts to generate a CMV vaccine have failed, but that was before we identified the GATE complex,” said Chris Benedict, Ph.D., associate professor at La Jolla Institute for Immunology. ”We hope that new strategies targeting GATE will improve our chances to combat CMV infection, and also perhaps cleanse our bodies of this lifelong infection.”
Erica Ollmann saphire, Ph.D., MBA, president & CEO of LJI and co-senior author, added that developing drugs or vaccines to inhibit CMV entry via GATE could considerably reduce the diseases caused by the virus in infants and immunocompromised patients.
What’s next
The research team is now focused on developing antiviral drugs and vaccines that specifically target the GATE complex to prevent CMV entry into cells, potentially leading to more effective treatments and preventive measures against this widespread virus.